News
Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label expansions to reduce the risk of cardiovascular issues. | Eli Lilly has presented phase 3 results showing its Mounjaro measures up to the company’s GLP-1 Trulicity in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease.
GlobalData on MSN8h
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmedEli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...
Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...
Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...
Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...
Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback